ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Of note is BT1, the first and most potent RNF114‐based PROTAC targeting BCR‐ABL to date, which has been shown to degrade the target and to have additional antileukemic effects by increasing the levels of the tumor suppressor p21 in CML cells.90